November 26, 2021
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved additional indications for a batch of medicines on November 25 including Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic heart failure. The green light makes it the...read more